dQM QICore Content Implementation Guide
2025.0.0 - CI Build
dQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/dqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/CMS347FHIRStatinPreventionTxCVD | Version: 1.0.000 | |||
Active as of 2025-08-20 | Responsible: Centers for Medicare & Medicaid Services (CMS) | Computable Name: CMS347FHIRStatinPreventionTxCVD | ||
Other Identifiers: Short Name: CMS347FHIR (use: usual, ), UUID:4d3066c5-88f7-48d2-8a93-9f946e1a41a6 (use: official, ), UUID:bcebaf84-db66-4cc4-ab1b-5c95eb02d300 (use: official, ), Publisher: 347FHIR (use: official, ) | ||||
Copyright/Legal: This electronic clinical quality measure (Measure) and related data specifications are owned and stewarded by the Centers for Medicare \& Medicaid Services (CMS). CMS contracted (Contract # 75FCMC18D0027/ Task Order #: 75FCMC24F0144) with the American Institutes for Research (AIR) to develop this electronic measure. AIR is not responsible for any use of the Measure. AIR makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and AIR has no liability to anyone who relies on such measures or specifications. Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. AIR disclaims all liability for use or accuracy of any third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024 American Medical Association. LOINC(R) is copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2024 World Health Organization. All Rights Reserved. |
Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:
All patients who were previously diagnosed with or currently have a diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR
Patients aged 20 to 75 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR
Patients aged 40-75 years with a diagnosis of diabetes; OR
Patients aged 40 to 75 with a 10-year ASCVD risk score of >= 20 percent.
Metadata | |
---|---|
Title | Statin Therapy for the Prevention and Treatment of Cardiovascular DiseaseFHIR |
Version | 1.0.000 |
Short Name | CMS347FHIR |
GUID (Version Independent) | urn:uuid:4d3066c5-88f7-48d2-8a93-9f946e1a41a6 |
GUID (Version Specific) | urn:uuid:bcebaf84-db66-4cc4-ab1b-5c95eb02d300 |
CMS Identifier | 347FHIR |
Effective Period | 2026-01-01 through 2026-12-31 |
Steward (Publisher) | Centers for Medicare & Medicaid Services (CMS) |
Developer | American Institutes for Research (AIR) |
Description | Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:
|
Copyright | This electronic clinical quality measure (Measure) and related data specifications are owned and stewarded by the Centers for Medicare & Medicaid Services (CMS). CMS contracted (Contract # 75FCMC18D0027/ Task Order #: 75FCMC24F0144) with the American Institutes for Research (AIR) to develop this electronic measure. AIR is not responsible for any use of the Measure. AIR makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and AIR has no liability to anyone who relies on such measures or specifications. Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. AIR disclaims all liability for use or accuracy of any third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024 American Medical Association. LOINC(R) is copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2024 World Health Organization. All Rights Reserved. |
Disclaimer | These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM]. |
Rationale | "Cardiovascular disease (CVD) is the leading cause of death in the United States, causing approximately 1 of every 3 deaths in the United States in 2015. In 2015, stroke caused approximately 1 of every 19 deaths in the United States and the estimated annual costs for CVD and stroke were $329.7 billion, including $199.2 billion in direct costs (hospital services, physicians and other professionals, prescribed medications, home health care, and other medical durables) and $130.5 billion in indirect costs from lost future productivity (cardiovascular and stroke premature deaths). CVD costs more than any other diagnostic group" (Benjamin et al., 2018). Data collected between 2011 and 2014 indicates that more than 94.6 million U.S. adults, 20 years or older, had total cholesterol levels equal to 200 mg/dL or more, while almost 28.5 million had levels 240 mg/dL or more (Benjamin et al., 2018). Elevated blood cholesterol is a major risk factor for CVD and statin therapy has been associated with a reduced risk of CVD. Numerous randomized trials have demonstrated that treatment with a statin reduces LDL-C and reduces the risk of major cardiovascular events by approximately 20 percent (Ference, 2015). In 2018, updated guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults were published (Grundy et al., 2019). This guideline was published by an Expert Panel, which synthesized evidence from randomized controlled trials to identify people most likely to benefit from cholesterol-lowering therapy. The American College of Cardiology (ACC)/American Heart Association (AHA)/Multi-society (MS) Guideline recommendations are intended to provide a strong evidence-based foundation for the treatment of blood cholesterol for the primary and secondary prevention and treatment of ASCVD in patients of all ages. The document concludes that the addition of statin therapy reduces the risk of ASCVD among high-risk individuals, defined as follows: individuals with clinical ASCVD, with LDL-C >= 190 mg/dL, with diabetes, or individuals with >= 20 percent risk of ASCVD as determined via use of an ASCVD risk estimator derived from the Pooled Cohort Equations (Grundy et al., 2019). One study surveying U.S. cardiology, primary care, and endocrinology practices found that 1 in 4 guideline-eligible patients were not on a statin and less than half were on the recommended statin intensity. Untreated and undertreated patients had significantly higher LDL-C levels than those receiving guideline-directed statin treatment (Navar et al., 2017). In a follow-up study authored by Nanna et al., the same clinics were divided into tertiles based on the percentage of patients with guideline-recommended statin use. The researchers found that patients in the high-tertile clinics were more likely to achieve target LDL-C levels than patients at the low- or mid-tertile clinics, and this held true when patients were stratified by primary and secondary prevention (Nanna et al., 2019a). Research also indicates that certain populations are far less likely to receive guideline-recommended statin therapy than others. A retrospective study of the National Health and Nutrition Examination Survey found that Black and Hispanic race or ethnicity, low income, lack of health insurance coverage, poor health care access, young age, and female gender are predictors of lower statin utilization (Gu et al., 2018). In particular, there is extensive evidence that women are far less likely than men to be prescribed guideline-recommended statin therapy (Nanna et al., 2019b), despite research showing that female patients with cardiovascular disease derive the same or greater benefit from statin therapy as male patients with cardiovascular disease (Puri et al., 2014). The Statin Safety Expert Panel that participated in a National Lipid Association (NLA) Statin Safety Task Force meeting in October 2013 reaffirms the general safety of statin therapy. The panel members concluded that for most patients requiring statin therapy, the potential benefits of statin therapy outweigh the potential risks. In general terms, the benefits of statins to prevent non-fatal myocardial infarction, revascularization, stroke, and CVD mortality, far outweigh any potential harm related to the drug (Jacobson, 2014). |
Clinical Recommendation Statement | This electronic clinical quality measure is intended to align with the 2018 ACC/AHA/MS Guideline on the Management of Blood Cholesterol (Grundy et al., 2019), which indicates the use of statins as the first line of cholesterol-lowering medication therapy to lower the risk of ASCVD among at-risk populations. Recommendations for Management of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults - Statin Treatment: Secondary Prevention:
Primary Prevention
The US Preventive Services Task Force (USPSTF) concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more of these CVD risk factors and an estimated 10-year CVD event risk of 7.5 percent to less than 10 percent has at least a small net benefit (USPSTF 2022). Statin Safety and Statin-Associated Side Effects A clinician–patient risk discussion is recommended before initiation of statin therapy to review net clinical benefit, weighing the potential for ASCVD risk reduction against the potential for statin-associated side effects, statin–drug interactions, and safety, while emphasizing that side effects can be addressed successfully (Class I Recommendation), (Grundy et al., 2019). |
Citation | 'Zhang, H., Plutzky, J., Shubina, M., & Turchin, A. (2016). Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PloS one, 11(5), e0155228. doi:10.1371/journal.pone.0155228 |
Citation | Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., …Munter, P. (2018). Heart disease and stroke statistics—2018 update: A report from the American Heart Association. Circulation, 137(12), e67-e492. doi.10.1161/CIR.0000000000000558 |
Citation | Ference, B.A. (2015). Statins and the risk of developing new-onset Type 2 diabetes: Expert analysis. Retrieved from https://www.acc.org/latest-in-cardiology/articles/2015/03/10/08/10/statins-and-the-risk-of-developing-new-onset-type-2-diabetes |
Citation | Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., …Yeboah, J. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 73 (24), e286-e343. doi.10.1016/j.jacc.2018.11.003 |
Citation | Gu, A., Kamat, S., Argulian, E. (2018). Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999–2014. Diabetes Research and Clinical Practice, 139, 1-10. doi:10.1016/j.diabres.2018.02.019 |
Citation | Jacobson, T. A. (2014). Executive summary: NLA Task Force on Statin Safety—2014 update. Journal of Clinical Lipidology, 8(3 Suppl.), S1-S4. doi:10.1016/jacl.2014.03.002 |
Citation | Nanna, M. G., Navar, A. M., Wang, Y. T., Li, S., Virani, S. S., Li, Z., … Peterson, E. D. (2019a). Practice-Level Variation in Statin use and Low-Density Lipoprotein Cholesterol Control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) Registry. American Heart Journal, 214, 113–124. doi:10.1016/j.ahj.2019.05.009 |
Citation | Nanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., … Navar, A. M. (2019b). Sex Differences in the use of Statins in Community Practice. Circulation. Cardiovascular Quality & Outcomes, 12(8), e005562. doi:10.1161/CIRCOUTCOMES.118.005562 |
Citation | Navar, M., Wang, T. Y., Li, S.,Robinson, J. G., Goldberg, A. C., Virani, S., …Peterson, E. D. (2017). Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. American Heart Journal, 193, 84-92. doi.10.1016/j.ahj.2017.08.005 |
Citation | Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., … Nicholls, S. J. (2014). Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC. Cardiovascular imaging, 7(10), 1013–1022. doi:10.1016/j.jcmg.2014.04.019 |
Citation | U.S. Preventive Services Task Force (USPSTF) (2022). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Journal of American Medical Association; 328(8):746-753. doi:10.1001/jama.2022.13044 |
Definition | Atherosclerotic Cardiovascular Disease (ASCVD) : Clinical ASCVD includes:
|
Definition | Lipoprotein Density Cholesterol (LDL-C) Result: A fasting or non-fasting LDL-C laboratory test performed and direct or calculated test result documented in the medical record. When both direct and calculated test results are available on the same day, the direct LDL-C test result should be used. |
Definition | Statin Medication Therapy List (NOTE: List does NOT include dosage): [Generic name] (Brand or trade name) and (-) Medication type, if applicable: [Atorvastatin] (Lipitor) - Statin [Fluvastatin] (Lescol XL or Lescol) - Statin [Lovastatin (Mevinolin)](Mevacor or Altoprev) - Statin [Pitavastatin] (Livalo or Zypitamag or Nikita) - Statin [Pravastatin Sodium] (Pravachol) - Statin [Rosuvastatin Calcium] (Crestor) - Statin [Simvastatin] (Zocor) - Statin [Amlodipine Besylate/Atorvastatin Calcium] (Caduet) – Fixed Dose Combination [Ezetimibe / Rosuvastatin] (Roszet) – Fixed Dose Combination [Ezetimibe/Simvastatin] (Vytorin) – Fixed Dose Combination |
Definition | Statin Therapy: Administration of one or more of a group of medications that are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia |
Definition | Statin-Associated Muscle Symptoms (SAMS): The 2018 ACC/AHA/MS Guideline (Grundy et al., 2019) includes the following SAMS: myalgias, myositis, myopathy, or statin-associated autoimmune myopathy. Patients who experience significant or repeated statin-associated muscle symptoms may prefer not to take or continue statin therapy and therefore may be removed from the denominator. |
Guidance (Usage) | Initial Population Guidance: The initial population covers four distinct populations. Use the following process to prevent counting patients more than once. Initial Population 1: All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure before the end of the measurement period.
Initial Population 2: Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory test result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia.
Initial Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period.
Initial Population 4: Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score of >= 20 percent during the measurement period.
Initial Population Guidance for Encounter: In order for the patient to be included in the Initial Population, the patient must have ONE initial population-eligible visit, defined as follows: outpatient visit, initial or established office visit, face-to-face interaction, preventive care services, or annual wellness visit. LDL-C Laboratory test result options: The measure can be reported for all patients with a documented LDL-C level recorded as follows: To meet Initial Population 1: There is no LDL-C result required. To meet Initial Population 2: If a patient has ANY previous laboratory result of LDL-C >= 190 mg/dL, report the highest value >= 190 mg/dL. To meet Initial Population 3: There is no LDL-C result required. To meet Initial Population 4: There is no LDL-C result required. The 10-year ASCVD risk assessment options: The 10-year ASCVD risk score is calculated using the Pooled Cohort Equations: 1) the 2013 ACC/AHA ASCVD Risk Estimator (maps to LOINC Code 79423-0) OR 2) the ACC Risk Estimator Plus (maps to LOINC Code 99055-6). If your EHR does not have either of these risk calculators, we recommend that you use the on-line versions. The 10-year ASCVD risk score (quantitative result, i.e., result.value, "%") must be documented in a structured field. The 10-year ASCVD risk assessment must be performed during the measurement period. Any documentation of a 10-year ASCVD risk score >=20 will qualify patient for the denominator population, even if risk score changes later in the measurement period. Numerator instructions and guidance:
Intensity of statin therapy in primary and secondary prevention: The expert panel of the 2018 ACC/AHA/MS Guidelines (Grundy et al., 2019) defines recommended intensity of statin therapy on the basis of the average expected LDL-C response to specific statin and dose. Although intensity of statin therapy is important in managing cholesterol, this measure assesses prescription of ANY statin therapy, irrespective of intensity. Assessment of appropriate intensity and dosage documentation added too much complexity to allow inclusion of statin therapy intensity in the measure at this time. Lifestyle modification coaching: A healthy lifestyle is important for the prevention of cardiovascular disease. However, lifestyle modification monitoring and documentation added too much complexity to allow its inclusion in the measure at this time. Millimoles per liter (mmol/L) must be converted to milligrams per deciliter (mg/dL) for reporting this measure. This eCQM is a patient-based measure. This FHIR-based measure has been derived from the QDM-based measure CMS347v9. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU6/) for more information on QI-Core and mapping recommendations from QDM to QI-Core STU 6 (https://hl7.org/fhir/us/qicore/STU6/qdm-to-qicore.html). |
Measure Group (Rate) (ID: Group_1) | |
Summary | All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure before the end of the measurement period and were taking a statin medication during the measure period |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Rate Aggregation | This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who have an active diagnosis of clinical ASCVD or ever had an ASCVD procedure. Population 2: Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 +Numerator 3)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) +(Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3)] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_1
Description: All patients who were previously diagnosed with or currently have a diagnosis of clinical ASCVD, including an ASCVD procedure Logic Definition: Initial Population 1 |
Denominator |
ID: Denominator_1
Description: Equals Initial Population Logic Definition: Denominator 1 |
Denominator Exclusion |
ID: DenominatorExclusion_1
Description:
|
Numerator |
ID: Numerator_1
Description: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_1
Description:
|
Measure Group (Rate) (ID: Group_2) | |
Summary | Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >=190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia and were taking a statin medication during the measure period |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Rate Aggregation | This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who have an active diagnosis of clinical ASCVD or ever had an ASCVD procedure. Population 2: Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 +Numerator 3)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) +(Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3)] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_2
Description: Patients aged 20 to 75 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >=190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia Logic Definition: Initial Population 2 |
Denominator |
ID: Denominator_2
Description: Equals Initial Population Logic Definition: Denominator 2 |
Denominator Exclusion |
ID: DenominatorExclusion_2
Description:
|
Numerator |
ID: Numerator_2
Description: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_2
Description:
|
Measure Group (Rate) (ID: Group_3) | |
Summary | Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and were taking a statin medication during the measure period |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Rate Aggregation | This measure is intended to have one reporting rate, which aggregates the following populations into a single performance rate for reporting purposes: Population 1: All patients who have an active diagnosis of clinical ASCVD or ever had an ASCVD procedure. Population 2: Patients aged >= 20 years at the beginning of the measurement period who have ever had a laboratory result of LDL-C >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia. Population 3: Patients aged 40 to 75 years at the beginning of the measurement period with an active diagnosis of Type 1 or Type 2 diabetes at any time during the measurement period. For the purposes of this measure, a single performance rate can be calculated as follows: Performance Rate = (Numerator 1 + Numerator 2 +Numerator 3)/ [(Denominator 1 - Denominator Exclusions 1- Denominator Exceptions 1) + (Denominator 2 - Denominator Exclusions 2 - Denominator Exceptions 2) +(Denominator 3 - Denominator Exclusions 3 - Denominator Exceptions 3)] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_3
Description: Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes Logic Definition: Initial Population 3 |
Denominator |
ID: Denominator_3
Description: Equals Initial Population Logic Definition: Denominator 3 |
Denominator Exclusion |
ID: DenominatorExclusion_3
Description:
|
Numerator |
ID: Numerator_3
Description: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_3
Description:
|
Measure Group (Rate) (ID: Group_4) | |
Summary | Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score (i.e., 2013 ACC/AHA ASCVD Risk Estimator or the ACC Risk Estimator Plus) of >= 20 percent and were taking a statin medication during the measure period |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_4
Description: Patients aged 40 to 75 at the beginning of the measurement period with a 10-year ASCVD risk score (i.e., 2013 ACC/AHA ASCVD Risk Estimator or the ACC Risk Estimator Plus) of >= 20 percent during the measurement period Logic Definition: Initial Population 4 |
Denominator |
ID: Denominator_4
Description: Equals Initial Population Logic Definition: Denominator 4 |
Denominator Exclusion |
ID: DenominatorExclusion_4
Description:
|
Numerator |
ID: Numerator_4
Description: Patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_4
Description:
|
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | https://madie.cms.gov/Library/CMS347FHIRStatinPreventionTxCVD |
Contents |
Population Criteria
Logic Definitions Terminology Dependencies Data Requirements |
Population Criteria | |
Measure Group (Rate) (ID: Group_1) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Measure Group (Rate) (ID: Group_2) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Measure Group (Rate) (ID: Group_3) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Measure Group (Rate) (ID: Group_4) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Logic Definitions | |
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: Hospice |
|
|
Logic Definition | Library Name: PalliativeCare |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: CMS347FHIRStatinPreventionTxCVD |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: CumulativeMedicationDuration |
|
|
Logic Definition | Library Name: CumulativeMedicationDuration |
|
|
Logic Definition | Library Name: CumulativeMedicationDuration |
|
|
Logic Definition | Library Name: Status |
|
|
Logic Definition | Library Name: Status |
|
|
Logic Definition | Library Name: Status |
|
|
Logic Definition | Library Name: Status |
|
|
Logic Definition | Library Name: Status |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Terminology | |
Code System |
Description: Code system ICD10CM
Resource: http://hl7.org/fhir/sid/icd-10-cm Canonical URL: http://hl7.org/fhir/sid/icd-10-cm |
Code System |
Description: Code system ConditionClinicalStatusCodes
Resource: http://terminology.hl7.org/CodeSystem/condition-clinical Canonical URL: http://terminology.hl7.org/CodeSystem/condition-clinical |
Code System |
Description: Code system ConditionVerificationStatusCodes
Resource: http://terminology.hl7.org/CodeSystem/condition-ver-status Canonical URL: http://terminology.hl7.org/CodeSystem/condition-ver-status |
Code System |
Description: Code system LOINC
Resource: http://loinc.org Canonical URL: http://loinc.org |
Code System |
Description: Code system SNOMEDCT
Resource: http://snomed.info/sct Canonical URL: http://snomed.info/sct |
Code System |
Description: Code system AllergyIntoleranceClinicalStatusCodes
Resource: http://terminology.hl7.org/CodeSystem/allergyintolerance-clinical Canonical URL: http://terminology.hl7.org/CodeSystem/allergyintolerance-clinical |
Value Set |
Description: Value set Myocardial Infarction
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.101 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.101 |
Value Set |
Description: Value set Cerebrovascular Disease Stroke or TIA
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.44 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.44 |
Value Set |
Description: Value set Atherosclerosis and Peripheral Arterial Disease
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.21 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.21 |
Value Set |
Description: Value set Ischemic Heart Disease or Other Related Diagnoses
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.46 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.46 |
Value Set |
Description: Value set Stable and Unstable Angina
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.47 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.47 |
Value Set |
Description: Value set PCI
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.67 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.67 |
Value Set |
Description: Value set CABG Surgeries
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 |
Value Set |
Description: Value set Carotid Intervention
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204 |
Value Set |
Description: Value set CABG or PCI Procedure
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 |
Value Set |
Description: Value set Annual Wellness Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 |
Value Set |
Description: Value set Office Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Value Set |
Description: Value set Outpatient Consultation
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 |
Value Set |
Description: Value set Outpatient Encounters for Preventive Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 |
Value Set |
Description: Value set Preventive Care Services Established Office Visit, 18 and Up
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 |
Value Set |
Description: Value set Preventive Care Services Individual Counseling
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 |
Value Set |
Description: Value set Preventive Care Services Initial Office Visit, 18 and Up
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 |
Value Set |
Description: Value set Preventive Care Services Other
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1150 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1150 |
Value Set |
Description: Value set Telemedicine Services
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 |
Value Set |
Description: Value set LDL Cholesterol
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 |
Value Set |
Description: Value set Familial Hypercholesterolemia
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.100 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.100 |
Value Set |
Description: Value set Diabetes
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 |
Value Set |
Description: Value set Low Intensity Statin Therapy
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 |
Value Set |
Description: Value set Moderate Intensity Statin Therapy
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 |
Value Set |
Description: Value set High Intensity Statin Therapy
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 |
Value Set |
Description: Value set Payer Type
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Value Set |
Description: Value set Breastfeeding
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 |
Value Set |
Description: Value set Rhabdomyolysis
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 |
Value Set |
Description: Value set Statin Allergen
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42 |
Value Set |
Description: Value set Encounter Inpatient
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 |
Value Set |
Description: Value set Hospice Encounter
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 |
Value Set |
Description: Value set Hospice Care Ambulatory
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 |
Value Set |
Description: Value set Hospice Diagnosis
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 |
Value Set |
Description: Value set Palliative Care Diagnosis
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 |
Value Set |
Description: Value set Palliative Care Encounter
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 |
Value Set |
Description: Value set Palliative Care Intervention
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 |
Value Set |
Description: Value set Hepatitis A
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 |
Value Set |
Description: Value set Hepatitis B
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 |
Value Set |
Description: Value set Liver Disease
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.42 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.42 |
Value Set |
Description: Value set Statin Associated Muscle Symptoms
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85 |
Value Set |
Description: Value set End Stage Renal Disease
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 |
Value Set |
Description: Value set Medical Reason
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007 |
Direct Reference Code |
Display: Subsequent non-ST elevation (NSTEMI) myocardial infarction
Code: I22.2 System: http://hl7.org/fhir/sid/icd-10-cm |
Direct Reference Code |
Display: Active
Code: active System: http://terminology.hl7.org/CodeSystem/condition-clinical |
Direct Reference Code |
Display: Recurrence
Code: recurrence System: http://terminology.hl7.org/CodeSystem/condition-clinical |
Direct Reference Code |
Display: Relapse
Code: relapse System: http://terminology.hl7.org/CodeSystem/condition-clinical |
Direct Reference Code |
Display: Confirmed
Code: confirmed System: http://terminology.hl7.org/CodeSystem/condition-ver-status |
Direct Reference Code |
Display: Unconfirmed
Code: unconfirmed System: http://terminology.hl7.org/CodeSystem/condition-ver-status |
Direct Reference Code |
Display: Provisional
Code: provisional System: http://terminology.hl7.org/CodeSystem/condition-ver-status |
Direct Reference Code |
Display: Differential
Code: differential System: http://terminology.hl7.org/CodeSystem/condition-ver-status |
Direct Reference Code |
Display: Cardiovascular disease 10Y risk [Likelihood]
Code: 99055-6 System: http://loinc.org |
Direct Reference Code |
Display: Cardiovascular disease 10Y risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013
Code: 79423-0 System: http://loinc.org |
Direct Reference Code |
Display: Male (finding)
Code: 248153007 System: http://snomed.info/sct |
Direct Reference Code |
Display: Female (finding)
Code: 248152002 System: http://snomed.info/sct |
Direct Reference Code |
Display: Active
Code: active System: http://terminology.hl7.org/CodeSystem/allergyintolerance-clinical |
Direct Reference Code |
Display: Discharge to home for hospice care (procedure)
Code: 428361000124107 System: http://snomed.info/sct |
Direct Reference Code |
Display: Discharge to healthcare facility for hospice care (procedure)
Code: 428371000124100 System: http://snomed.info/sct |
Direct Reference Code |
Display: Hospice care [Minimum Data Set]
Code: 45755-6 System: http://loinc.org |
Direct Reference Code |
Display: Yes (qualifier value)
Code: 373066001 System: http://snomed.info/sct |
Direct Reference Code |
Display: Functional Assessment of Chronic Illness Therapy - Palliative Care Questionnaire (FACIT-Pal)
Code: 71007-9 System: http://loinc.org |
Dependencies | |
Dependency |
Description: QICore model information
Resource: http://hl7.org/fhir/Library/QICore-ModelInfo Canonical URL: http://hl7.org/fhir/Library/QICore-ModelInfo |
Dependency |
Description: Library QICoreCommon
Resource: https://madie.cms.gov/Library/QICoreCommon|4.0.000 Canonical URL: https://madie.cms.gov/Library/QICoreCommon|4.0.000 |
Dependency |
Description: Library FHIRHelpers
Resource: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 Canonical URL: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library SDE
Resource: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 Canonical URL: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 |
Dependency |
Description: Library CMD
Resource: https://madie.cms.gov/Library/CumulativeMedicationDuration|6.0.000 Canonical URL: https://madie.cms.gov/Library/CumulativeMedicationDuration|6.0.000 |
Dependency |
Description: Library Hospice
Resource: https://madie.cms.gov/Library/Hospice|6.18.000 Canonical URL: https://madie.cms.gov/Library/Hospice|6.18.000 |
Dependency |
Description: Library Status
Resource: https://madie.cms.gov/Library/Status|1.15.000 Canonical URL: https://madie.cms.gov/Library/Status|1.15.000 |
Dependency |
Description: Library PalliativeCare
Resource: https://madie.cms.gov/Library/PalliativeCare|1.18.000 Canonical URL: https://madie.cms.gov/Library/PalliativeCare|1.18.000 |
Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-patient Must Support Elements: birthDate, birthDate.value, url, extension |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.101 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code Code(s): http://hl7.org/fhir/sid/icd-10-cm#I22.2: 'Subsequent non-ST elevation (NSTEMI) myocardial infarction' |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.44 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.21 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.46 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.47 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.100 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.42 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.67 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 |
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure Must Support Elements: code, performed, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1150 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, hospitalization, hospitalization.dischargeDisposition, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-lab Must Support Elements: code, value, effective, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-screening-assessment Must Support Elements: code, value, effective, status, status.value Code Filter(s): Path: code Code(s): http://loinc.org#99055-6: 'Cardiovascular disease 10Y risk [Likelihood]' |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-screening-assessment Must Support Elements: code, value, effective, status, status.value Code Filter(s): Path: code Code(s): http://loinc.org#79423-0: 'Cardiovascular disease 10Y risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013' |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-screening-assessment Must Support Elements: code, value, effective, status, status.value Code Filter(s): Path: code Code(s): http://loinc.org#45755-6: 'Hospice care [Minimum Data Set]' |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-screening-assessment Must Support Elements: code, effective, value, status, status.value Code Filter(s): Path: code Code(s): http://loinc.org#71007-9: 'Functional Assessment of Chronic Illness Therapy - Palliative Care Questionnaire (FACIT-Pal)' |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, intent, intent.value, dosageInstruction, dispenseRequest, dispenseRequest.expectedSupplyDuration, dispenseRequest.quantity, dispenseRequest.numberOfRepeatsAllowed, dispenseRequest.numberOfRepeatsAllowed.value, dispenseRequest.validityPeriod Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, intent, intent.value, dosageInstruction, dispenseRequest, dispenseRequest.expectedSupplyDuration, dispenseRequest.quantity, dispenseRequest.numberOfRepeatsAllowed, dispenseRequest.numberOfRepeatsAllowed.value, dispenseRequest.validityPeriod Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, intent, intent.value, dosageInstruction, dispenseRequest, dispenseRequest.expectedSupplyDuration, dispenseRequest.quantity, dispenseRequest.numberOfRepeatsAllowed, dispenseRequest.numberOfRepeatsAllowed.value, dispenseRequest.validityPeriod Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication.reference.value, authoredOn, authoredOn.value, status, status.value, intent, intent.value, dosageInstruction, dispenseRequest, dispenseRequest.expectedSupplyDuration, dispenseRequest.quantity, dispenseRequest.numberOfRepeatsAllowed, dispenseRequest.numberOfRepeatsAllowed.value, dispenseRequest.validityPeriod |
Data Requirement |
Type: Medication
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medication Must Support Elements: id.value, code |
Data Requirement |
Type: Coverage
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-coverage Must Support Elements: type, period Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 |
Data Requirement |
Type: AllergyIntolerance
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-allergyintolerance Must Support Elements: code, onset, clinicalStatus Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42 |
Data Requirement |
Type: ServiceRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-servicerequest Must Support Elements: code, authoredOn, authoredOn.value, status, status.value, intent, intent.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 |
Data Requirement |
Type: AdverseEvent
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-adverseevent Must Support Elements: event, date, date.value, recordedDate, recordedDate.value Code Filter(s): Path: event ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationnotrequested Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, reasonCode Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationnotrequested Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, reasonCode Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationnotrequested Must Support Elements: medication, authoredOn, authoredOn.value, status, status.value, reasonCode Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 |
Generated using version 0.4.8 of the sample-content-ig Liquid templates |